Do we have enough evidence to support the use of SGLT2 inhibitors for MACE reduction in patients with advance kidney disease?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Do we have enough evidence to support the use of SGLT2 inhibitors for MACE reduction in patients with advance kidney disease?

Published:2019-12 Issue: Volume:70 Page:e25-e26
ISSN:0953-6205
Container-title:European Journal of Internal Medicine
language:en
Short-container-title:European Journal of Internal Medicine

Author:

Doshi Rajkumar^ORCID,Meghji Zahara,Kumar Ashish,Shariff Mariam^ORCID,Adalja Devina

Publisher

Elsevier BV

Subject

Internal Medicine

Reference5 articles.

1. For, on behalf of primary care diabetes E. SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: a systematic review and meta-analysis;Seidu;Prim Care Diabetes,2018

2. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials;Zelniker;Lancet,2019

3. Which is the main molecular target responsible for the cardiovascular benefits in the EMPA-REG OUTCOME trial? A journey through the kidney, the heart and other interesting places;Luconi;Nutr Metab Cardiovasc Dis,2016

4. Cardiovascular and renal benefits of SGLT2 inhibitors: A narrative review;Rabizadeh;Int J Endocrinol Metab,2019

5. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients;Ferrannini;J Clin Invest,2014

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP